Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies

Jefferies analyst Andrew Tsai raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $380.00 (from $275.00) while maintaining a Buy rating.

The analyst comments "Based on our (+) KOL discussions, we believe Auvelity's combined peak sales in major depression (MDD) and Alzheimer's agitation (AADAD) could surpass $6B+ (or $3B apiece), up from a $610M+ runrate in MDD-only - still conservative vs mgmt's $8B guidance. Ultimately, $6B of sales x 3x multiple (long IP tail) = $18B+ valuation (vs $12.5B cap), making AXSM's late-stage CNS pipeline (10+ indications) mostly call options - raising PT to $380."

You May Also Be Interested In

• Alphabet Sees FY26 Capex $195B To $205B, Saw $180B To $190B
• Berenberg Downgrades Boliden AB (BOL:SS) (BDNNF) to Hold
• Bernstein SocGen Group Upgrades Sona BLW Precision (SONACOMS:IN) to Outperform